` NOVO B (Novo Nordisk A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

NOVO B
vs
OMX Copenhagen 25

Over the past 12 months, NOVO B has underperformed OMX Copenhagen 25, delivering a return of -52% compared to the OMX Copenhagen 25's 12% drop.

Stocks Performance
NOVO B vs OMX Copenhagen 25

Loading

Performance Gap
NOVO B vs OMX Copenhagen 25

Loading
NOVO B
OMX Copenhagen 25
Difference

Performance By Year
NOVO B vs OMX Copenhagen 25

Loading
NOVO B
OMX Copenhagen 25
Add Stock

Competitors Performance
Novo Nordisk A/S vs Peers

OMX Copenhagen 25
NOVO B
LLY
JNJ
ROG
NOVN
Add Stock

Novo Nordisk A/S
Glance View

Economic Moat
Wide
Market Cap
2T DKK
Industry
Pharmaceuticals

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
637.6 DKK
Undervaluation 31%
Intrinsic Value
Price
Back to Top